MwanzoABUS • NASDAQ
add
Arbutus Biopharma Corp
Bei iliyotangulia
$ 4.50
Bei za siku
$ 4.47 - $ 4.62
Bei za mwaka
$ 2.71 - $ 5.10
Thamani ya kampuni katika soko
883.56M USD
Wastani wa hisa zilizouzwa
2.67M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.05M | -33.23% |
Matumizi ya uendeshaji wa biashara | 3.69M | -21.71% |
Mapato halisi | -3.76M | 70.03% |
Kiwango cha faida halisi | -357.37 | 55.11% |
Mapato kwa kila hisa | — | — |
EBITDA | -7.63M | 34.28% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 91.47M | -25.40% |
Jumla ya mali | 94.62M | -28.16% |
Jumla ya dhima | 18.04M | -47.46% |
Jumla ya hisa | 76.58M | — |
hisa zilizosalia | 195.48M | — |
Uwiano wa bei na thamani | 11.25 | — |
Faida inayotokana na mali | -19.87% | — |
Faida inayotokana mtaji | -23.48% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -3.76M | 70.03% |
Pesa kutokana na shughuli | -4.68M | 54.63% |
Pesa kutokana na uwekezaji | -1.36M | -110.15% |
Pesa kutokana na ufadhili | 1.64M | 15.41% |
Mabadiliko halisi ya pesa taslimu | -4.40M | -198.13% |
Mtiririko huru wa pesa | -1.95M | 77.37% |
Kuhusu
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2007
Makao Makuu
Tovuti
Wafanyakazi
19
